Global Iron Deficiency Anemia Therapy Market
Размер рынка в млрд долларов США
CAGR :
% 
 Прогнозируемый период |
2024 –2031 |
 Размер рынка (базовый год) |
USD 4.86 Billion |
 Размер рынка (прогнозируемый год) |
USD 10.08 Billion |
 CAGR |
% |
| Основные игроки рынка |
>Глобальный рынок терапии железодефицитной анемии по терапии (парентеральная терапия железом и терапия пероральными препаратами железа), области терапии (акушерство и гинекология, заболевания почек, застойная сердечная недостаточность (ЗСН), онкология , воспалительные заболевания кишечника и другие), население (взрослые, гериатрические и педиатрические), конечный пользователь (больницы, специализированные клиники, учреждения по уходу на дому и другие), канал сбыта (больничная аптека, аптеки и розничные аптеки, а также интернет-аптеки) — тенденции отрасли и прогноз до 2031 года.
Анализ и размер рынка терапии железодефицитной анемии
Глобальный рынок терапии железодефицитной анемии переживает значительный рост, обусловленный ростом заболеваемости железодефицитной анемией, внедрением на рынок новых препаратов и тенденцией к социальному здравоохранению в области женского здоровья, в частности анемии. Рынок характеризуется наличием большого количества игроков, предлагающих широкий спектр методов лечения, адаптированных для удовлетворения разнообразных потребностей поставщиков медицинских услуг в регионе.
По данным анализа Data Bridge Market Research, ожидается, что мировой рынок терапии железодефицитной анемии достигнет 10,08 млрд долларов США к 2031 году по сравнению с 4,86 млрд долларов США в 2023 году, а среднегодовой темп роста составит 10,0% в прогнозируемый период с 2024 по 2031 год. Ожидается, что рост заболеваемости железодефицитной анемией будет способствовать расширению рынка.
|
Отчет Метрика |
Подробности |
|
Прогнозируемый период |
2024-2031 |
|
Базовый год |
2023 |
|
Исторический год |
2022 (настраиваемый 2016-2021) |
|
Количественные единицы |
Доход в млрд долларов США |
|
Охваченные сегменты |
Терапия (парентеральная терапия железом и терапия пероральным железом), Терапевтическая область (акушерство и гинекология, заболевания почек , застойная сердечная недостаточность (ЗСН) , онкология, воспалительные заболевания кишечника и другие), Население (взрослые, гериатрические и педиатрические), Конечный пользователь (больницы, специализированные клиники, учреждения по уходу на дому и другие), Канал распространения (больничная аптека, аптеки и розничные аптеки, а также интернет-аптеки) |
|
Страны, охваченные |
Мексика, Канада, США, Великобритания, Германия, Италия, Франция, Испания, Бельгия, Швейцария, Турция, Россия, Нидерланды, Остальная Европа, Индия, Китай, Япония, Австралия, Таиланд, Малайзия, Южная Корея, Филиппины, Сингапур, Индонезия, Остальная часть Азиатско-Тихоокеанского региона, Аргентина, Бразилия, Остальная часть Южной Америки, Южная Африка, Египет, Саудовская Аравия, ОАЭ, Израиль, Остальной Ближний Восток и Африка |
|
Охваченные участники рынка |
Vifor Pharma Ltd., DAIICHI SANKYO COMPANY, LIMITED, AFT Pharmaceuticals., Sanofi, Pfizer Inc., Fresenius Kabi AG, PHARMACOSMOS Therapeutics Inc, Thorne, Lupin, BLACKMORES, Shield Therapeutics plc, Aspen Pharmacare Australia Pty Ltd. Здравоохранение и другие. |
Определение рынка
Iron deficiency anemia therapy is a treatment approach aimed at replenishing iron stores and correcting anemia caused by iron deficiency. The primary goal of therapy is to restore normal iron levels and hemoglobin production, thereby improving symptoms such as fatigue, weakness, and shortness of breath. Therapy typically involves oral iron supplementation, which can be in the form of ferrous sulfate, ferrous gluconate, or ferric citrate, and may be administered alone or in combination with other medications to enhance absorption and efficacy. In severe cases, intravenous iron therapy may be necessary, and in some instances, blood transfusions may be required to rapidly increase hemoglobin levels.
Global Iron-Deficiency Anemia Therapy Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
- Rising Incidences of Iron Deficiency Anemia
Anemia is defined as a low concentration of blood hemoglobin. It is a health problem that affects all economical sections of world ranging from low-, middle- and high-income countries. Significant adverse health consequences of anemia along with worse impacts on economic and social development.
Anemia occurs due to various etiologies, with the most common contributor is iron deficiency. Approximately 50% of cases of anemia cases are caused due to iron deficiency, but the ratio probably varies due to various factors.
Other causes of anemia include other deficiencies of micronutrient (e.g. vitamins A, folate, riboflavin and B12), chronic and acute infections (e.g. cancer, tuberculosis, malaria, and HIV), and acquired or inherited disorders that affect synthesis of hemoglobin, red blood cell (RBC) production or survival.
Iron deficiency anemia is said to be the most common form of anemia found globally. In this condition, blood lacks sufficient healthy red blood cells (RBC’s) which functions to carry oxygen to the tissue of the body’s Iron deficiency anemia is caused due to insufficient iron.
The lack of proper nutrition and various inflammations in body, which renders the poor absorption of the iron, leads to increased prevalence of iron deficiency anemia.
For instance,
- According to a report by India Spend, published in 2016, 20% of maternal deaths in India were caused by anemia and was the associate cause in 50% of maternal deaths in October 2016. Low birth weight among babies and risking them for lifelong issues involving physical growth and cognitive development is caused by anemia. According to statistics, the efficiency of anemic children reduces to 2.5% as adults compared to their healthier peers.
- According to Global Nutrition Report 2017, it reported that just over half (51%) of women of reproductive age (15 to 49 years) are anemic in India and according to the report in the fourth National Family Health Survey (NFHS-IV) in 2015-16 it is estimated that 53% of the women were anemic in India in the reproductive age
Introduction of Novel Drugs in the Market
Innovation drives progress, the availability of novel drugs, lead products and biological products often means new hope and better treatment options for patients and advancement in health care for public worldwide. Some of the products are new and innovative with novel approach that have never been used in clinical practice and have potential benefits to cure the persisting ailment in the population worldwide. The various drugs and therapies are made with advanced research and development and thorough testing using subjects to check their efficiency.
For instance,
- In December 2023, according to an article published by FDA, the U.S. FDA approved two landmark treatments, Casgevy and Lyfgenia, as the first cell-based gene therapies for sickle cell disease (SCD) in patients 12 years and older. Notably, Casgevy is the first FDA-approved treatment to use novel genome editing technology, marking a significant advancement in gene therapy
- These breakthroughs will drive the global iron-deficiency anemia therapy market by highlighting the potential for innovative treatments and encouraging further research and development in anemia-related therapies
- In September 2023, according to an article published by GSK plc., GSK plc. announced FDA approval of Ojjaara (momelotinib) for treating intermediate or high-risk myelofibrosis, including primary and secondary myelofibrosis, in adults with anemia. Ojjaara, a once-daily oral JAK1/JAK2 and ACVR1 inhibitor, is the only approved treatment for both newly diagnosed and previously treated myelofibrosis patients with anemia, addressing anemia, constitutional symptoms, and splenomegaly.
Opportunity
- Increasing Research and Development Activities
Herbs, fungi and plants for curing anemia have been used in medicinal traditions indigenous for millennia. The increased prevalence of anemia worldwide is causing a social problem in the world leading to more rigorous research and development need in the respected field. After decades of persistent advocacy and education, rigorous research and development employing iron deficiency anemia as tools of healing and discovery are abundant.
Currently, various research studies are taking place in private practice sites and in research institutions supported by for-profit and non-profit organizations, along with individual research studies. This research includes clinical trials for intravenous therapy for the treatment of iron deficiency anemia associated with chronic heart disease, chronic kidney diseases dependent on dialysis or non-dependent of dialysis.
For instance,
- In March 2022, according to an article published by National Heart, Lung, and Blood Institute, NHLBI researchers have contributed to treatments for aplastic anemia, a rare condition where the bone marrow fails to produce enough blood cells. They developed immunosuppressant drugs to manage this disorder. NHLBI-funded research continues to explore the causes of anemia, investigating red blood cell production in healthy individuals and those with anemia. Additionally, the NHLBI and NCI launched the Blood and Marrow Transplant Clinical Trials Network in 2001 to advance transplantation therapies, potentially curing certain types of anemia
- These efforts present opportunities for the global iron-deficiency anemia therapy market by fostering innovation in treatment approaches, including genetic therapies, and supporting clinical trials that could lead to new, effective treatments for anemia worldwide
Restraint/Challenge
- Limitation in Diagnosing Iron Deficiency Anemia in Inflammatory Conditions
Iron deficiency anemia is a major health problem across globe, which represents one of the growing nonlethal disease situations across globe and is frequently seen in ordinary clinical practice. Timely prognosis and diagnosis are crucial because of the important role played by iron in the functioning of all organ systems. In spite of its prevalence, iron deficiency is generally overlooked, in patients with inflammatory conditions, mostly due to the mixture of symptoms and definitions provided in clinical preparation guidelines.
Usually, the most well-known risk groups for iron deficiency are the malnourished people, those who needs high iron inputs, such as adolescents or pregnant women, and individuals with chronic blood loss, for instance, from gastrointestinal bleeding or heavy uterine. The growing attention is now being shifted towards the iron status of patients associated with inflammatory conditions, which incline them to iron deficiency.
The most frequent of these are Chronic Kidney Disease (CKD), Chronic Heart Failure (CHF), and Inflammatory Bowel Disease (IBD). Estimation of iron deficiency in patients associated with inflammatory diseases is least diagnosed due to lack of diagnosing measures or markers.
For instance,
- In July 2022, according to an article published by PubMed Central, diagnosing and treating iron-deficiency anemia (IDA) relies on accurate detection of iron deficiency, which is complicated by factors like inflammation, diet, and metabolic variations. Current biomarkers such as hemoglobin (Hb), serum ferritin, and transferrin saturation levels are affected by these factors, making them unreliable in certain conditions. For instance, ferritin levels can rise during inflammation, masking true iron levels. The use of multiple markers like the sTfR-F index shows promise in overcoming these challenges, but there remains a need for more robust diagnostic tools
- This diagnostic complexity poses a significant challenge for the global iron-deficiency anemia therapy market, necessitating the development of more accurate and sensitive diagnostic methods that can reliably identify and monitor iron status in diverse patient populations, including those with underlying inflammatory conditions or specific genetic disorders like sickle cell anemia
- In 2018, according to a report published in the international journal of chronic diseases by Department of Medicine, Agaplesion Markus Hospital, Goethe University, Germany and Interdisciplinary Crohn Colitis Center Rhein-Main, Germany. The estimates of iron deficiency in groups of people having inflammatory conditions have changed a lot between studies due to contradictory definitions and diverse patient assortment criteria. They found that approximately 24–85% of patients with CKD, 50% of patients with CHF and 45% of patients with IBD are iron-deficient
Recent Developments
- In June 2023, GSK has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), recommending the authorization of daprodustat for the treatment of symptomatic anemia associated with chronic kidney disease (CKD) in adults undergoing chronic maintenance dialysis. This recommendation marks a significant step towards providing a new therapeutic option for managing anemia in CKD patients on long-term dialysis, addressing an important unmet medical need in this population
- In March 2024, Vafseo approved by the U.S. FDA for the treatment of anemia due to chronic kidney disease in dialysis-dependent adult patients. CSL Vifor is pleased that its partner Akebia Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Vafseo (vadadustat) tablets for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months. Vafseo is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) developed by Akebia
- In February 2024, Lupin launched a Cyanocobalamin Nasal Spray, 500 mcg/spray (One Spray per Device), after having received an approval from the United States Food and Drug Administration (U.S. FDA)
- In December 2023, Novartis receives FDA approval for Fabhalta (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH announced that the U.S. Food and Drug Administration (FDA) approved Fabhalta (iptacopan) as the first oral monotherapy for the treatment of adults with Paroxysmal Nocturnal Hemoglobinuria (PNH). Fabhalta is a Factor B inhibitor that acts proximally in the alternative complement pathway of the immune system, providing comprehensive control of red blood cell (RBC) destruction within and outside the blood vessels (intra- and extravascular hemolysis [IVH and EVH])
- In March 2024, Ferinject approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure announced that Health Canada has authorized Ferinject (ferric carboxymaltose) for the intravenous (IV) treatment of iron deficiency anemia in adult and pediatric patients one year of age and older when oral iron preparations are not tolerated or are ineffective, as well as for the treatment of iron deficiency in adult patients with heart failure
Global Iron-Deficiency Anemia Therapy Market Scope
The global iron-deficiency anemia therapy market is segmented into five notable segments based on therapy, therapy area, population, end user, and distribution channel. The growth amongst these segments will help you analyze major growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
Therapy
- Parenteral Iron Therapy
- Oral Iron Therapy
On the basis of therapy, the market is segmented into parenteral iron therapy and oral iron therapy.
Therapy Area
- Obstetrics and Gynecology
- Renal Diseases
- Congestive Heart Failure (CHF)
- Oncology
- Inflammatory Bowel Disease
- Others
On the basis of therapy area, the market is segmented into obstetrics and gynecology, renal diseases, Congestive Heart Failure (CHF), oncology, inflammatory bowel disease and others.
Population
- Adults
- Geriatric
- Pediatric
On the basis of population, the market is segmented into adults, geriatric, and pediatric.
End User
- Hospitals
- Specialty Clinics
- Home Care Setting
- Others
On the basis of end user, the market is segmented into hospitals, specialty clinics, home care setting, and others.
Distribution Channel
- Hospital Pharmacy
- Drug Stores and Retail Pharmacies
- Online Pharmacies
On the basis of distribution channel, the market is segmented into hospital pharmacy, drug stores, retail pharmacies, online pharmacies.
Global Iron-Deficiency Anemia Therapy Market Regional Analysis/Insights
The global iron-deficiency anemia therapy market is analyzed and market size insights and trends are provided based on therapy, therapy area, population, end user, and distribution channel as referenced above.
The countries covered in this market report are Mexico, Canada, U.S., U.K., Germany, Italy, France, Spain, Belgium, Switzerland, Turkey, Russia, Netherlands, rest of Europe, India, China, Japan, Australia, Thailand, Malaysia, South Korea, Philippines, Singapore, Indonesia, rest of Asia-Pacific, Argentina, Brazil, rest of South America, South Africa, Egypt, Saudi Arabia, U.A.E., Israel, rest of Middle East and Africa.
Ожидается, что Северная Америка будет доминировать на мировом рынке терапии железодефицитной анемии из-за своей развитой инфраструктуры здравоохранения. Ожидается, что США будут доминировать в регионе Северной Америки из-за высокой распространенности этого состояния, надежной политики возмещения расходов и значительных инвестиций в исследования и разработки. Ожидается, что Великобритания будет доминировать в регионе Европы из-за правительственной склонности к социальному здравоохранению в отношении женского здоровья, в частности анемии. Ожидается, что Индия будет доминировать на рынке терапии железодефицитной анемии в Азиатско-Тихоокеанском регионе.
Раздел отчета по странам также содержит отдельные факторы, влияющие на рынок, и изменения в регулировании рынка, которые влияют на текущие и будущие тенденции рынка. Такие данные, как анализ цепочки создания стоимости вверх и вниз по течению, технические тенденции, анализ пяти сил Портера и тематические исследования, являются некоторыми из указателей, используемых для прогнозирования рыночного сценария для отдельных стран. Кроме того, при предоставлении прогнозного анализа данных по странам учитываются наличие и доступность глобальных брендов и их проблемы из-за большой или малой конкуренции со стороны местных и отечественных брендов, влияние внутренних тарифов и торговые пути.
Анализ конкурентной среды и доли мирового рынка терапии железодефицитной анемии
Конкурентная среда мирового рынка терапии железодефицитной анемии содержит сведения о конкурентах. Включены сведения о компании, ее финансах, полученном доходе, рыночном потенциале, инвестициях в исследования и разработки, новых рыночных инициативах, глобальном присутствии, производственных площадках и объектах, производственных мощностях, сильных и слабых сторонах компании, запуске продукта, широте и широте продукта и доминировании в применении. Приведенные выше данные касаются только фокуса компаний на мировом рынке терапии железодефицитной анемии.
Некоторые из основных игроков, работающих на мировом рынке терапии железодефицитной анемии, включают Vifor Pharma Ltd., Daiichi Sankyo Company, Limited, AFT Pharmaceuticals., Sanofi, Pfizer Inc., Fresenius Kabi AG, Pharmacosmos Therapeutics Inc, Thorne, Lupin, Blackmores, Shield Therapeutics plc, Aspen Pharmacare Australia Pty Ltd. Health Care и другие.
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Интерактивная панель анализа данных
- Панель анализа компании для возможностей с высоким потенциалом роста
- Доступ аналитика-исследователя для настройки и запросов
- Анализ конкурентов с помощью интерактивной панели
- Последние новости, обновления и анализ тенденций
- Используйте возможности сравнительного анализа для комплексного отслеживания конкурентов
Содержание
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET END USER COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 SECONDARY SOURCES
2.11 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTAL ANALYSIS
4.2 PORTER’S FIVE FORCES
5 MARKET OVERVIEW
5.1 DRIVERS
5.1.1 RISING INCIDENCES OF IRON DEFICIENCY ANEMIA
5.1.2 INTRODUCTION OF NOVEL DRUGS IN THE MARKET
5.1.3 INCLINATION TOWARDS SOCIAL HEALTHCARE ON WOMEN HEALTH SPECIFICALLY ANEMIA
5.2 RESTRAINTS
5.2.1 STRINGENT REGULATIONS FOR IRON DEFICIENCY ANEMIA THERAPY
5.2.2 AVAILABILITY OF ALTERNATIVE TREATMENT OPTIONS
5.2.3 HIGH COST OF THERAPY
5.3 OPPORTUNITIES
5.3.1 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES
5.3.2 ENHANCING DRUG QUALITY AND REIMBURSEMENT POLICIES
5.3.3 STRATEGIC ACQUISITIONS AND MERGERS
5.4 CHALLENGES
5.4.1 LIMITATION IN DIAGNOSING IRON DEFICIENCY ANEMIA IN INFLAMMATORY CONDITIONS
5.4.2 EMERGING DRUG RESISTANCE
6 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY
6.1 OVERVIEW
6.2 PARENTERAL IRON THERAPY
6.3 ORAL IRON THERAPY
7 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA
7.1 OVERVIEW
7.2 OBSTETRICS AND GYNECOLOGY
7.3 RENAL DISEASES
7.4 CONGESTIVE HEART FAILURE (CHF)
7.5 ONCOLOGY
7.6 INFLAMMATORY BOWEL DISEASE
7.7 OTHERS
8 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION
8.1 OVERVIEW
8.2 ADULTS
8.3 GERIATRIC
8.4 PEDIATRIC
9 GLOBAL HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER
9.1 OVERVIEW
9.2 HOSPITALS
9.3 SPECIALTY CLINICS
9.4 HOME CARE SETTING
9.5 OTHERS
10 GLOBAL DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL
10.1 OVERVIEW
10.2 HOSPITAL PHARMACY
10.3 DRUG STORES AND RETAIL PHARMACIES
10.4 ONLINE PHARMACIES
11 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY REGION
11.1 OVERVIEW
11.2 NORTH AMERICA
11.2.1 MEXICO
11.2.2 CANADA
11.2.3 U.S.
11.3 EUROPE
11.3.1 U.K.
11.3.2 GERMANY
11.3.3 ITALY
11.3.4 FRANCE
11.3.5 SPAIN
11.3.6 BELGIUM
11.3.7 SWITZERLAND
11.3.8 TURKEY
11.3.9 RUSSIA
11.3.10 NETHERLANDS
11.3.11 REST OF EUROPE
11.4 ASIA-PACIFIC
11.4.1 INDIA
11.4.2 CHINA
11.4.3 JAPAN
11.4.4 AUSTRALIA
11.4.5 MALAYSIA
11.4.6 SOUTH KOREA
11.4.7 PHILIPPINES
11.4.8 SINGAPORE
11.4.9 INDONESIA
11.4.10 REST OF ASIA-PACIFIC
11.5 SOUTH AMERICA
11.5.1 ARGENTINA
11.5.2 BRAZIL
11.5.3 REST OF SOUTH AMERICA
11.6 MIDDLE EAST AND AFRICA
11.6.1 SOUTH AFRICA
11.6.2 EGYPT
11.6.3 SAUDI ARABIA
11.6.4 U.A.E.
11.6.5 ISRAEL
11.6.6 REST OF MIDDLE EAST AND AFRICA
12 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: GLOBAL
12.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
12.3 COMPANY SHARE ANALYSIS: EUROPE
12.4 COMPANY SHARE ANALYSIS: ASIA - PACIFIC
13 SWOT ANALYSIS
14 COMPANY PROFILE
14.1 VIFOR PHARMA LTD.
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUE ANALYSIS
14.1.3 COMPANY SHARE ANALYSIS
14.1.4 PRODUCT PORTFOLIO
14.1.5 RECENT DEVELOPMENT
14.2 DAIICHI SANKYO COMPANY, LIMITED.
14.2.1 COMPANY SNAPSHOT
14.2.2 COMPANY SHARE ANALYSIS
14.2.3 PRODUCT/ SERVICE PORTFOLIO
14.2.4 RECENT DEVELOPMENT
14.3 AFT PHARMACEUTICALS
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 PRODUCT/ SERVICE PORTFOLIO
14.3.4 RECENT DEVELOPMENT
14.4 SANOFI
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 COMPANY SHARE ANALYSIS
14.4.4 PRODUCT PORTFOLIO
14.4.5 RECENT DEVELOPMENT
14.5 PFIZER INC.
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 COMPANY SHARE ANALYSIS
14.5.4 PRODUCT PORTFOLIO
14.5.5 RECENT DEVELOPMENT
14.6 AKEBIA THERAPEUTICS, INC
14.6.1 COMPANY SNAPSHOT
14.6.2 REVENUE ANALYSIS
14.6.3 PRODUCT PORTFOLIO
14.6.4 RECENT DEVELOPMENT
14.7 ALKEM.
14.7.1 COMPANY SNAPSHOT
14.7.2 REVENUE ANALYSIS
14.7.3 PRODUCT PORTFOLIO
14.7.4 RECENT DEVELOPMENT
14.8 ASPEN PHARMACARE AUSTRALIA PTY LTD.
14.8.1 COMPANY SNAPSHOT
14.8.2 PRODUCT/ SERVICE PORTFOLIO
14.8.3 RECENT DEVELOPMENT
14.9 BLACKMORES
14.9.1 COMPANY SNAPSHOT
14.9.2 REVENUE ANALYSIS
14.9.3 PRODUCT/ SERVICE PORTFOLIO
14.9.4 RECENT DEVELOPMENT
14.1 FARLEX
14.10.1 COMPANY SNAPSHOT
14.10.2 PRODUCT PORTFOLIO
14.10.3 RECENT DEVELOPMENT
14.11 FRESENIUS KABI AG
14.11.1 COMPANY SNAPSHOT
14.11.2 REVENUE ANALYSIS
14.11.3 PRODUCT PORTFOLIO
14.11.4 RECENT DEVELOPMENTS
14.12 GLAXOSMITHKLINE PLC.
14.12.1 COMPANY SNAPSHOT
14.12.2 REVENUE ANALYSIS
14.12.3 PRODUCT PORTFOLIO
14.12.4 RECENT DEVELOPMENTS
14.13 LUPIN
14.13.1 COMPANY SNAPSHOT
14.13.2 REVENUE ANALYSIS
14.13.3 PRODUCT PORTFOLIO
14.13.4 RECENT DEVELOPMENT
14.14 NOVARTIS AG
14.14.1 COMPANY SNAPSHOT
14.14.2 REVENUE ANALYSIS
14.14.3 PRODUCT PORTFOLIO
14.14.4 RECENT DEVELOPMENT
14.15 ORION CORPORATION
14.15.1 COMPANY SNAPSHOT
14.15.2 REVENUE ANALYSIS
14.15.3 PRODUCT PORTFOLIO
14.15.4 RECENT DEVELOPMENT
14.16 PHARMACOSMOS A/S
14.16.1 COMPANY SNAPSHOT
14.16.2 PRODUCT PORTFOLIO
14.16.3 RECENT DEVELOPMENT
14.17 SHIELD THERAPEUTICS PLC
14.17.1 COMPANY SNAPSHOT
14.17.2 REVENUE ANALYSIS
14.17.3 PRODUCT PORTFOLIO
14.17.4 RECENT DEVELOPMENT
14.18 TEVA PHARMACEUTICAL INDUSTRIES LTD.
14.18.1 COMPANY SNAPSHOT
14.18.2 REVENUE ANALYSIS
14.18.3 PRODUCT PORTFOLIO
14.18.4 RECENT DEVELOPMENT
14.19 COTHORNE
14.19.1 COMPANY SNAPSHOT
14.19.2 PRODUCT/ SERVICE PORTFOLIO
14.19.3 RECENT DEVELOPMENT
14.2 VIATRIS INC.
14.20.1 COMPANY SNAPSHOT
14.20.2 REVENUE ANALYSIS
14.20.3 PRODUCT PORTFOLIO
14.20.4 RECENT DEVELOPMENTS
14.21 ZYDUS GROUP
14.21.1 COMPANY SNAPSHOT
14.21.2 REVENUE ANALYSIS
14.21.3 PRODUCT PORTFOLIO
14.21.4 RECENT DEVELOPMENT
15 QUESTIONNAIRE
16 RELATED REPORTS
Список таблиц
TABLE 1 PREVALENCE OF ANEMIA IN CHILDREN OF AFRICA AND ASIA
TABLE 2 IRON DEFICIENCY ANEMIA THERAPEUTICS R&D ACTIVITIES
TABLE 3 CAUSES, PREVALENCE, AND CLINICAL CONSEQUENCES OF IRON DEFICIENCY IN INFLAMMATORY CONDITIONS
TABLE 4 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 5 GLOBAL PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 6 GLOBAL PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 7 GLOBAL ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 8 GLOBAL ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 9 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 10 GLOBAL OBSTETRICS AND GYNECOLOGY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 11 GLOBAL RENAL DISEASES IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 12 GLOBAL CONGESTIVE HEART FAILURE (CHF) IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 13 GLOBAL ONCOLOGY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 14 GLOBAL INFLAMMATORY BOWEL DISEASE IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 15 GLOBAL OTHERS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 16 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 17 GLOBAL ADULTS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 18 GLOBAL GERIATRIC IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 19 GLOBAL PEDIATRIC IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 20 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 21 GLOBAL HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 22 GLOBAL HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 23 GLOBAL SPECIALTY CLINICS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 24 GLOBAL HOME CARE SETTING IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 25 GLOBAL OTHERS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 26 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 27 GLOBAL HOSPITAL PHARMACY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 28 GLOBAL DRUG STORES AND RETAIL PHARMACIES IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 29 GLOBAL ONLINE PHARMACIES IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 30 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 31 NORTH AMERICA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 32 NORTH AMERICA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 33 NORTH AMERICA PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 34 NORTH AMERICA ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 35 NORTH AMERICA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 36 NORTH AMERICA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 37 NORTH AMERICA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 38 NORTH AMERICA HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 39 NORTH AMERICA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 40 MEXICO IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 41 MEXICO PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 42 MEXICO ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 43 MEXICO IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 44 MEXICO IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 45 MEXICO IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 46 MEXICO HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 47 MEXICO IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 48 CANADA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 49 CANADA PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 50 CANADA ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 51 CANADA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 52 CANADA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 53 CANADA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 54 CANADA HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 55 CANADA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 56 U.S. IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 57 U.S. PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 58 U.S. ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 59 U.S. IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 60 U.S. IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 61 U.S. IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 62 U.S. HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 63 U.S. IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 64 EUROPE IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 65 EUROPE IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 66 EUROPE PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 67 EUROPE ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 68 EUROPE IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 69 EUROPE IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 70 EUROPE IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 71 EUROPE HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 72 EUROPE IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 73 U.K. IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 74 U.K. PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 75 U.K. ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 76 U.K. IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 77 U.K. IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 78 U.K. IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 79 U.K. HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 80 U.K. IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 81 GERMANY IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 82 GERMANY PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 83 GERMANY ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 84 GERMANY IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 85 GERMANY IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 86 GERMANY IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 87 GERMANY HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 88 GERMANY IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 89 ITALY IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 90 ITALY PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 91 ITALY ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 92 ITALY IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 93 ITALY IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 94 ITALY IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 95 ITALY HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 96 ITALY IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 97 FRANCE IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 98 FRANCE PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 99 FRANCE ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 100 FRANCE IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 101 FRANCE IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 102 FRANCE IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 103 FRANCE HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 104 FRANCE IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 105 SPAIN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 106 SPAIN PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 107 SPAIN ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 108 SPAIN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 109 SPAIN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 110 SPAIN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 111 SPAIN HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 112 SPAIN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 113 BELGIUM IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 114 BELGIUM PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 115 BELGIUM ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 116 BELGIUM IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 117 BELGIUM IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 118 BELGIUM IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 119 BELGIUM HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 120 BELGIUM IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 121 SWITZERLAND IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 122 SWITZERLAND PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 123 SWITZERLAND ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 124 SWITZERLAND IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 125 SWITZERLAND IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 126 SWITZERLAND IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 127 SWITZERLAND HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 128 SWITZERLAND IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 129 TURKEY IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 130 TURKEY PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 131 TURKEY ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 132 TURKEY IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 133 TURKEY IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 134 TURKEY IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 135 TURKEY HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 136 TURKEY IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 137 RUSSIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 138 RUSSIA PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 139 RUSSIA ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 140 RUSSIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 141 RUSSIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 142 RUSSIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 143 RUSSIA HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 144 RUSSIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 145 NETHERLANDS IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 146 NETHERLANDS PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 147 NETHERLANDS ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 148 NETHERLANDS IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 149 NETHERLANDS IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 150 NETHERLANDS IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 151 NETHERLANDS HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 152 NETHERLANDS IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 153 EREST OF EUROPE IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 154 ASIA-PACIFIC IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 155 ASIA-PACIFIC IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 156 ASIA-PACIFIC PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 157 ASIA-PACIFIC ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 158 ASIA-PACIFIC IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 159 ASIA-PACIFIC IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 160 ASIA-PACIFIC IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 161 ASIA-PACIFIC HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 162 ASIA-PACIFIC IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 163 INDIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 164 INDIA PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 165 INDIA ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 166 INDIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 167 INDIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 168 INDIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 169 INDIA HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 170 INDIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 171 CHINA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 172 CHINA PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 173 CHINA ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 174 CHINA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 175 CHINA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 176 CHINA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 177 CHINA HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 178 CHINA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 179 JAPAN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 180 JAPAN PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 181 JAPAN ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 182 JAPAN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 183 JAPAN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 184 JAPAN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 185 JAPAN HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 186 JAPAN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 187 AUSTRALIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 188 AUSTRALIA PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 189 AUSTRALIA ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 190 AUSTRALIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 191 AUSTRALIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 192 AUSTRALIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 193 AUSTRALIA HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 194 AUSTRALIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 195 THAILAND IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 196 THAILAND PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 197 THAILAND ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 198 THAILAND IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 199 THAILAND IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 200 THAILAND IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 201 THAILAND HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 202 THAILAND IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 203 MALAYSIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 204 MALAYSIA PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 205 MALAYSIA ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 206 MALAYSIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 207 MALAYSIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 208 MALAYSIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 209 MALAYSIA HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 210 MALAYSIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 211 SOUTH KOREA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 212 SOUTH KOREA PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 213 SOUTH KOREA ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 214 SOUTH KOREA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 215 SOUTH KOREA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 216 SOUTH KOREA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 217 SOUTH KOREA HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 218 SOUTH KOREA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 219 PHILIPPINES IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 220 PHILIPPINES PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 221 PHILIPPINES ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 222 PHILIPPINES IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 223 PHILIPPINES IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 224 PHILIPPINES IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 225 PHILIPPINES HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 226 PHILIPPINES IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 227 SINGAPORE IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 228 SINGAPORE PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 229 SINGAPORE ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 230 SINGAPORE IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 231 SINGAPORE IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 232 SINGAPORE IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 233 SINGAPORE HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 234 SINGAPORE IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 235 INDONESIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 236 INDONESIA PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 237 INDONESIA ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 238 INDONESIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 239 INDONESIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 240 INDONESIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 241 INDONESIA HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 242 INDONESIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 243 REST OF ASIA-PACIFIC IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 244 SOUTH AMERICA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 245 SOUTH AMERICA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 246 SOUTH AMERICA PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 247 SOUTH AMERICA ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 248 SOUTH AMERICA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 249 SOUTH AMERICA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 250 SOUTH AMERICA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 251 SOUTH AMERICA HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 252 SOUTH AMERICA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 253 ARGENTINA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 254 ARGENTINA PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 255 ARGENTINA ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 256 ARGENTINA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 257 ARGENTINA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 258 ARGENTINA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 259 ARGENTINA HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 260 ARGENTINA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 261 BRAZIL IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 262 BRAZIL PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 263 BRAZIL ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 264 BRAZIL IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 265 BRAZIL IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 266 BRAZIL IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 267 BRAZIL HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 268 BRAZIL IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 269 REST OF SOUTH AMERICA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 270 MIDDLE EAST AND AFRICA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 271 MIDDLE EAST AND AFRICA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 272 MIDDLE EAST AND AFRICA PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 273 MIDDLE EAST AND AFRICA ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 274 MIDDLE EAST AND AFRICA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 275 MIDDLE EAST AND AFRICA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 276 MIDDLE EAST AND AFRICA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 277 MIDDLE EAST AND AFRICA HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 278 MIDDLE EAST AND AFRICA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 279 SOUTH AFRICA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 280 SOUTH AFRICA PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 281 SOUTH AFRICA ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 282 SOUTH AFRICA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 283 SOUTH AFRICA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 284 SOUTH AFRICA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 285 SOUTH AFRICA HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 286 SOUTH AFRICA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 287 EGYPT IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 288 EGYPT PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 289 EGYPT ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 290 EGYPT IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 291 EGYPT IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 292 EGYPT IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 293 EGYPT HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 294 EGYPT IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 295 SAUDI ARABIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 296 SAUDI ARABIA PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 297 SAUDI ARABIA ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 298 SAUDI ARABIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 299 SAUDI ARABIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 300 SAUDI ARABIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 301 SAUDI ARABIA HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 302 SAUDI ARABIA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 303 U.A.E. IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 304 U.A.E. PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 305 U.A.E. ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 306 U.A.E. IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 307 U.A.E. IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 308 U.A.E. IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 309 U.A.E. HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 310 U.A.E. IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 311 ISRAEL IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
TABLE 312 ISRAEL PARENTERAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 313 ISRAEL ORAL IRON THERAPY IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 314 ISRAEL IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY AREA, 2022-2031 (USD MILLION)
TABLE 315 ISRAEL IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY POPULATION, 2022-2031 (USD MILLION)
TABLE 316 ISRAEL IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 317 ISRAEL HOSPITALS IN IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 318 ISRAEL IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 319 REST OF MIDDLE EAST AND AFRICA IRON-DEFICIENCY ANEMIA THERAPY MARKET, BY THERAPY, 2022-2031 (USD MILLION)
Список рисунков
FIGURE 1 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: SEGMENTATION
FIGURE 2 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: END USER COVERAGE GRID
FIGURE 8 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: DBMR MARKET POSITION GRID
FIGURE 9 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: SEGMENTATION
FIGURE 10 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: STRATEGIC DECISIONS
FIGURE 11 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: SEGMENTATION TWO SEGMENTS COMPRISE
FIGURE 12 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: EXECUTIVE SUMMARY
FIGURE 13 RISING INCIDENCES OF IRON DEFICIENCY ANEMIA ARE DRIVING THE GROWTH OF THE GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET FROM 2024 TO 2031
FIGURE 14 THE THERAPY SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET IN 2024 AND 2031
FIGURE 15 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2024 TO 2031
FIGURE 16 ASIA-PACIFIC IS THE FASTEST-GROWING REGION FOR IRON-DEFICIENCY ANEMIA THERAPY MARKET MANUFACTURERS IN THE FORECAST PERIOD OF 2024 TO 2031
FIGURE 17 DRIVERS, RESTRAINT, OPPORTUNITIES AND CHALLENGE OF GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET
FIGURE 18 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: BY THERAPY, 2023
FIGURE 19 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: BY THERAPY, 2024-2031 (USD MILLION)
FIGURE 20 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: BY THERAPY, CAGR (2024-2031)
FIGURE 21 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: BY THERAPY, LIFELINE CURVE
FIGURE 22 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: BY THERAPY AREA, 2023
FIGURE 23 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: BY THERAPY AREA, 2024-2031 (USD MILLION)
FIGURE 24 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: BY THERAPY AREA, CAGR (2024-2031)
FIGURE 25 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: BY THERAPY AREA, LIFELINE CURVE
FIGURE 26 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: BY POPULATION, 2023
FIGURE 27 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: BY POPULATION, 2024-2031 (USD MILLION)
FIGURE 28 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: BY POPULATION, CAGR (2024-2031)
FIGURE 29 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: BY POPULATION, LIFELINE CURVE
FIGURE 30 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: BY END USER, 2023
FIGURE 31 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: BY END USER, 2024-2031 (USD MILLION)
FIGURE 32 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: BY END USER, CAGR (2024-2031)
FIGURE 33 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: BY END USER, LIFELINE CURVE
FIGURE 34 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 35 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)
FIGURE 36 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 37 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 38 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: SNAPSHOT (2023)
FIGURE 39 GLOBAL IRON-DEFICIENCY ANEMIA THERAPY MARKET: COMPANY SHARE 2023 (%)
FIGURE 40 NORTH AMERICA IRON-DEFICIENCY ANEMIA THERAPY MARKET: COMPANY SHARE 2023 (%)
FIGURE 41 EUROPE IRON-DEFICIENCY ANEMIA THERAPY MARKET: COMPANY SHARE 2023 (%)
FIGURE 42 ASIA - PACIFIC IRON-DEFICIENCY ANEMIA THERAPY MARKET: COMPANY SHARE 2023 (%)
Методология исследования
Сбор данных и анализ базового года выполняются с использованием модулей сбора данных с большими размерами выборки. Этап включает получение рыночной информации или связанных данных из различных источников и стратегий. Он включает изучение и планирование всех данных, полученных из прошлого заранее. Он также охватывает изучение несоответствий информации, наблюдаемых в различных источниках информации. Рыночные данные анализируются и оцениваются с использованием статистических и последовательных моделей рынка. Кроме того, анализ доли рынка и анализ ключевых тенденций являются основными факторами успеха в отчете о рынке. Чтобы узнать больше, пожалуйста, запросите звонок аналитика или оставьте свой запрос.
Ключевой методологией исследования, используемой исследовательской группой DBMR, является триангуляция данных, которая включает в себя интеллектуальный анализ данных, анализ влияния переменных данных на рынок и первичную (отраслевую экспертную) проверку. Модели данных включают сетку позиционирования поставщиков, анализ временной линии рынка, обзор рынка и руководство, сетку позиционирования компании, патентный анализ, анализ цен, анализ доли рынка компании, стандарты измерения, глобальный и региональный анализ и анализ доли поставщика. Чтобы узнать больше о методологии исследования, отправьте запрос, чтобы поговорить с нашими отраслевыми экспертами.
Доступна настройка
Data Bridge Market Research является лидером в области передовых формативных исследований. Мы гордимся тем, что предоставляем нашим существующим и новым клиентам данные и анализ, которые соответствуют и подходят их целям. Отчет можно настроить, включив в него анализ ценовых тенденций целевых брендов, понимание рынка для дополнительных стран (запросите список стран), данные о результатах клинических испытаний, обзор литературы, обновленный анализ рынка и продуктовой базы. Анализ рынка целевых конкурентов можно проанализировать от анализа на основе технологий до стратегий портфеля рынка. Мы можем добавить столько конкурентов, о которых вам нужны данные в нужном вам формате и стиле данных. Наша команда аналитиков также может предоставить вам данные в сырых файлах Excel, сводных таблицах (книга фактов) или помочь вам в создании презентаций из наборов данных, доступных в отчете.
